Sangivamycin is a natural product originally isolated from Streptomyces rimosus, which is a nucleoside analogue. It acts as an inhibitor of protein kinase C. It has antibiotic, antiviral and anti-cancer properties and has been investigated for various medical applications, though never approved for clinical use itself. However, a number of related derivatives continue to be researched.Smith HC, et al. Methods of treating and inhibiting ebola virus infection. Patent application CA3040540, Oyagen Inc, 17 May 2018
Oyagen, a biotechnology company, has been developing sangivamycin or OYA1, which showed efficacy against Ebola infections, as a broad spectrum antiviral for COVID-19. Tonix Pharmaceuticals licensed OYA1 from Oyagen in April 2021 to develop it for the treatment of COVID-19 and it is now called TNX-3500. In July 2022, Tonix announced that it was terminating development of TNX-3500, an antiviral inhibitor of SARS-CoV-2, and the associated licence agreement with OyaGen, Inc. was expected to be terminated, effective September 20, 2022.
See also CMX521 (methylated analogue) GS-441524 NITD008 Pyrazofurin
References